AWH Stock Overview
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Aspira Women's Health Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.75 |
| 52 Week High | US$5.65 |
| 52 Week Low | US$0.67 |
| Beta | 1.44 |
| 11 Month Change | -22.29% |
| 3 Month Change | -27.55% |
| 1 Year Change | -77.48% |
| 33 Year Change | -97.56% |
| 5 Year Change | -93.34% |
| Change since IPO | -99.98% |
Recent News & Updates
Shareholder Returns
| AWH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.2% | 0.9% | 2.2% |
| 1Y | -77.5% | 21.9% | 32.6% |
Return vs Industry: AWH underperformed the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: AWH underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| AWH volatility | |
|---|---|
| AWH Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AWH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AWH's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 64 | Nicole Sandford | aspirawh.com |
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company’s products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1’s high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
Aspira Women's Health Inc. Fundamentals Summary
| AWH fundamental statistics | |
|---|---|
| Market cap | US$12.05m |
| Earnings (TTM) | -US$14.79m |
| Revenue (TTM) | US$8.96m |
1.3x
P/S Ratio-0.8x
P/E RatioIs AWH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AWH income statement (TTM) | |
|---|---|
| Revenue | US$8.96m |
| Cost of Revenue | US$3.75m |
| Gross Profit | US$5.21m |
| Other Expenses | US$20.00m |
| Earnings | -US$14.79m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.92 |
| Gross Margin | 58.12% |
| Net Profit Margin | -165.07% |
| Debt/Equity Ratio | -62.0% |
How did AWH perform over the long term?
See historical performance and comparison